| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3.9 | 1.6 |
| Net income | -29.9 | -15.5 |
| EPS (diluted, $ a share) | $-0.54 | $-19.18 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +147.3% |
|---|
10-Q filed with the SEC, NASDAQ: AKTS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aktis Oncology, Inc.: key numbers
- Share price
- $16.16Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aktis Oncology, Inc.
All →Aktis Oncology Financial Results
Aktis Oncology reported financial results for the third quarter of 2026, highlighting the initiation of its third Phase 1b clinical trial (BActinium-2) for AKY-2519. The company also operationalized its in-house GMP manufacturing facility in Boston and remains on track to present preliminary clinical data for its lead programs in 2027.
- Term
- Q3 2026
“Aktis is on a trajectory to redefine radiopharmaceuticals as a major pillar of cancer treatment by expanding the modality to more targets, broader indications, and larger patient populations. In the third quarter, we continued to make tremendous progress operationalizing this vision.”
Matthew Roden, Ph.D., President and Chief Executive Officer
“With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies.”
Matthew Roden, Ph.D., President and Chief Executive Officer
Aktis Oncology CMO Akos Czibere Sells $259K of Stock
Akos Czibere, CMO, sold 12,500 shares of Aktis Oncology, Inc. at $20.19 to $21.03 a share (average $20.69) in 2 transactions, worth $259K in total on Sep 23, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $259K
- Shares
- 12,500
- Average price
- $20.69
- Role
- CMO
- Holding change
- -100.0%
- Trade date
- Sep 23, 2026